Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer
KA Lyseng-Williamson - Pharmacoeconomics, 2010 - Springer
Erlotinib (Tarceva®), an oral epidermal growth factor receptor tyrosine kinase inhibitor, is
associated with modest improvements in survival in patients with advanced non-small cell …
associated with modest improvements in survival in patients with advanced non-small cell …
Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.
KA Lyseng-Williamson - Pharmacoeconomics, 2010 - europepmc.org
Erlotinib (Tarceva), an oral epidermal growth factor receptor tyrosine kinase inhibitor, is
associated with modest improvements in survival in patients with advanced non-small cell …
associated with modest improvements in survival in patients with advanced non-small cell …
Erlotinib
KA Lyseng-Williamson - PharmacoEconomics, 2010 - search.proquest.com
Erlotinib (Tarceva®), an oral epidermal growth factor receptor tyrosine kinase inhibitor, is
associated with modest improvements in survival in patients with advanced non-small cell …
associated with modest improvements in survival in patients with advanced non-small cell …
Erlotinib: A Pharmacoeconomic Review of its Use in Advanced Non-Small Cell Lung Cancer.
KA Lyseng-Williamson - PharmacoEconomics, 2010 - search.ebscohost.com
Erlotinib (Tarceva®), an oral epidermal growth factor receptor tyrosine kinase inhibitor, is
associated with modest improvements in survival in patients with advanced non-small cell …
associated with modest improvements in survival in patients with advanced non-small cell …
Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer
KA Lyseng-Williamson - PharmacoEconomics, 2010 - go.gale.com
Erlotinib (Tarceva [R]), an oral epidermal growth factor receptor tyrosine kinase inhibitor, is
associated with modest improvements in survival in patients with advanced non-small cell …
associated with modest improvements in survival in patients with advanced non-small cell …
Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer
KA Lyseng-Williamson - PharmacoEconomics, 2010 - pubmed.ncbi.nlm.nih.gov
Erlotinib (Tarceva), an oral epidermal growth factor receptor tyrosine kinase inhibitor, is
associated with modest improvements in survival in patients with advanced non-small cell …
associated with modest improvements in survival in patients with advanced non-small cell …